

# Urological Cancer Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/U2628C5228EMEN.html>

Date: April 2018

Pages: 131

Price: US\$ 3,480.00 (Single User License)

ID: U2628C5228EMEN

## Abstracts

### Report Summary

Urological Cancer Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023

Main market players of Urological Cancer Drugs in EMEA, with company and product introduction, position in the Urological Cancer Drugs market

Market status and development trend of Urological Cancer Drugs by types and applications

Cost and profit status of Urological Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Urological Cancer Drugs market as:

EMEA Urological Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Urological Cancer Drugs Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (Radium Ra 223 Dichloride)  
Jevtana (Cabazitaxel)  
Inlyta (Axitinib)  
Votrient (Pazopanib Hydrochloride)  
Sutent (Sunitinib Malate)  
Zytiga (Abiraterone Acetate)  
Xtandi (Enzalutamide)  
Opdivo (Nivolumab)  
Provenge (Sipuleucel-T)

EMEA Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Prostate Cancer  
Bladder Cancer  
Kidney Cancer  
Testicular Cancer

EMEA Urological Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):

Novartis  
Pfizer  
Johnson & Johnson  
AstraZeneca  
Astellas  
Bristol-Myers Squibb  
Abbott Laboratories  
Celgene Corporation  
Dendreon Corporation  
Ferring Pharmaceuticals  
GlaxoSmithKline  
Indevus Pharmaceuticals Inc  
Ipsen  
Roche Healthcare  
Sanofi S.A.  
Tolmar Inc

In a word, the report provides detailed statistics and analysis on the state of the

industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS**

- 1.1 Definition of Urological Cancer Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Drugs
  - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
  - 1.2.2 Jevtana (Cabazitaxel)
  - 1.2.3 Inlyta (Axitinib)
  - 1.2.4 Votrient (Pazopanib Hydrochloride)
  - 1.2.5 Sutent (Sunitinib Malate)
  - 1.2.6 Zytiga (Abiraterone Acetate)
  - 1.2.7 Xtandi (Enzalutamide)
  - 1.2.8 Opdivo (Nivolumab)
  - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Drugs
  - 1.3.1 Prostate Cancer
  - 1.3.2 Bladder Cancer
  - 1.3.3 Kidney Cancer
  - 1.3.4 Testicular Cancer
- 1.4 Development History of Urological Cancer Drugs
- 1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
  - 1.5.1 EMEA Urological Cancer Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Urological Cancer Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Urological Cancer Drugs in EMEA by Regions
  - 2.2.1 Consumption Volume of Urological Cancer Drugs in EMEA by Regions
  - 2.2.2 Revenue of Urological Cancer Drugs in EMEA by Regions
- 2.3 Market Analysis of Urological Cancer Drugs in EMEA by Regions
  - 2.3.1 Market Analysis of Urological Cancer Drugs in Europe 2013-2017
  - 2.3.2 Market Analysis of Urological Cancer Drugs in Middle East 2013-2017
  - 2.3.3 Market Analysis of Urological Cancer Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Urological Cancer Drugs in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Urological Cancer Drugs in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Urological Cancer Drugs by Regions 2018-2023

## **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole EMEA Market Status by Types

#### 3.1.1 Consumption Volume of Urological Cancer Drugs in EMEA by Types

#### 3.1.2 Revenue of Urological Cancer Drugs in EMEA by Types

### 3.2 EMEA Market Status by Types in Major Countries

#### 3.2.1 Market Status by Types in Europe

#### 3.2.2 Market Status by Types in Middle East

#### 3.2.3 Market Status by Types in Africa

### 3.3 Market Forecast of Urological Cancer Drugs in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Urological Cancer Drugs in EMEA by Downstream Industry

### 4.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Major Countries

#### 4.2.1 Demand Volume of Urological Cancer Drugs by Downstream Industry in Europe

#### 4.2.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Middle East

#### 4.2.3 Demand Volume of Urological Cancer Drugs by Downstream Industry in Africa

### 4.3 Market Forecast of Urological Cancer Drugs in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS**

### 5.1 EMEA Economy Situation and Trend Overview

### 5.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

### 6.1 Sales Volume of Urological Cancer Drugs in EMEA by Major Players

### 6.2 Revenue of Urological Cancer Drugs in EMEA by Major Players

### 6.3 Basic Information of Urological Cancer Drugs by Major Players

#### 6.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Players

#### 6.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Players

- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Novartis
  - 7.1.1 Company profile
  - 7.1.2 Representative Urological Cancer Drugs Product
  - 7.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.2 Pfizer
  - 7.2.1 Company profile
  - 7.2.2 Representative Urological Cancer Drugs Product
  - 7.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 Johnson & Johnson
  - 7.3.1 Company profile
  - 7.3.2 Representative Urological Cancer Drugs Product
  - 7.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.4 AstraZeneca
  - 7.4.1 Company profile
  - 7.4.2 Representative Urological Cancer Drugs Product
  - 7.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.5 Astellas
  - 7.5.1 Company profile
  - 7.5.2 Representative Urological Cancer Drugs Product
  - 7.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
- 7.6 Bristol-Myers Squibb
  - 7.6.1 Company profile
  - 7.6.2 Representative Urological Cancer Drugs Product
  - 7.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.7 Abbott Laboratories
  - 7.7.1 Company profile
  - 7.7.2 Representative Urological Cancer Drugs Product
  - 7.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott

## Laboratories

### 7.8 Celgene Corporation

#### 7.8.1 Company profile

#### 7.8.2 Representative Urological Cancer Drugs Product

#### 7.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation

### 7.9 Dendreon Corporation

#### 7.9.1 Company profile

#### 7.9.2 Representative Urological Cancer Drugs Product

#### 7.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation

### 7.10 Ferring Pharmaceuticals

#### 7.10.1 Company profile

#### 7.10.2 Representative Urological Cancer Drugs Product

#### 7.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals

### 7.11 GlaxoSmithKline

#### 7.11.1 Company profile

#### 7.11.2 Representative Urological Cancer Drugs Product

#### 7.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

### 7.12 Indevus Pharmaceuticals Inc

#### 7.12.1 Company profile

#### 7.12.2 Representative Urological Cancer Drugs Product

#### 7.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc

### 7.13 Ipsen

#### 7.13.1 Company profile

#### 7.13.2 Representative Urological Cancer Drugs Product

#### 7.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen

### 7.14 Roche Healthcare

#### 7.14.1 Company profile

#### 7.14.2 Representative Urological Cancer Drugs Product

#### 7.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare

### 7.15 Sanofi S.A.

#### 7.15.1 Company profile

#### 7.15.2 Representative Urological Cancer Drugs Product

#### 7.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi

S.A.

7.16 Tolmar Inc

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS**

8.1 Industry Chain of Urological Cancer Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS**

9.1 Cost Structure Analysis of Urological Cancer Drugs

9.2 Raw Materials Cost Analysis of Urological Cancer Drugs

9.3 Labor Cost Analysis of Urological Cancer Drugs

9.4 Manufacturing Expenses Analysis of Urological Cancer Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER DRUGS**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation



## 12.2 Data Source

### 12.2.1 Secondary Sources

### 12.2.2 Primary Sources

## 12.3 Reference

## I would like to order

Product name: Urological Cancer Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/U2628C5228EMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U2628C5228EMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970